Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 50,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 31, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCB160058, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Completed No phase listed Observational

Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation

NCT05611216
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Simultaneous Cochlear Implantation During Translabyrinthine Resection of Vestibular Schwannoma

NCT03958006
View directory record Official record
Conditions
Vestibular Schwannoma, Cochlear Implantation
Interventions
Cochlear implant
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 31, 2026, 2:15 PM EDT
Completed No phase listed Observational

An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

NCT00923104
View directory record Official record
Conditions
Breast Cancer, Healthy Volunteer, Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 31, 2026, 2:15 PM EDT
Terminated Not applicable Interventional Results available

Mobile Intervention - Physical Activity in Cancer Treatment

NCT03671304
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Fitbit Versa
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Informational Meetings for Planning and Coordinating Treatment

NCT04330833
View directory record Official record
Conditions
End of Life, Communication, Cancer Metastatic
Interventions
Novel Communication Intervention, Enhanced Usual Care Parent Education
Other
Lead sponsor
Indiana University
Other
Eligibility
1 Month to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Terminated Phase 1 Interventional

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT02134067
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS-119, Paclitaxel
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 31, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

NCT05236036
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide
Drug · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed

NCT00877071
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
LC Bead loaded with doxorubicin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

NCT05323734
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 31, 2026, 2:15 PM EDT
Active, not recruiting No phase listed Observational

Validation Study on the Impact of Decipher® Testing - VANDAAM Study

NCT02723734
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher® Testing
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Bay Pines, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764
View directory record Official record
Conditions
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

NCT06943664
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery
Procedure · Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064
View directory record Official record
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

NCT03531632
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
MGD007 + MGA012
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 31, 2026, 2:15 PM EDT
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 31, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT07477587
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Springdale, Arkansas • Jacksonville, Florida • Margate, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Olanzapine in Patients With Advanced Cancer and Weight Loss

NCT00489593
View directory record Official record
Conditions
Advanced Cancer, Weight Loss
Interventions
Olanzapine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Massage Therapy for Cancer-Related Fatigue

NCT00039793
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms
Interventions
Moderate-intensity and low-intensity bodywork therapy
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 31, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

NCT01599793
View directory record Official record
Conditions
Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 31, 2026, 2:15 PM EDT